Boehringer Ingelheim Launched New Swine Vaccine

The pharmaceutical company introduced a new single-dose vaccine to target predominant virus genotypes in Canada.

Updated on Oct. 13, 2026 in Pet Health

Boehringer Ingelheim Launched New Swine Vaccine

Live Poll

Would you adopt new veterinary technology if it promised to improve your business's performance?

Boehringer Ingelheim has launched INGELVAC CIRCOFLEX AD in Canada to protect pig herds against porcine circovirus type 2. This new single-dose vaccine is designed to address the challenges posed by evolving virus genotypes.

Why it matters

The industry observed that PCV2d has become the predominant genotype within the Canadian swine population over the past decade. This vaccine aims to provide broader coverage to effectively manage the risk of porcine circovirus associated disease.

The new vaccine combines porcine circovirus type 2a and type 2d genotypes into a single-dose administration. It serves as an updated solution following the previous INGELVAC CIRCOFLEX product.

The players

Boehringer Ingelheim

This is a research-driven pharmaceutical company that focuses on developing innovative therapies for humans and animals.

The details

Porcine circovirus associated disease often results in significant symptoms for pigs, including weight loss, diarrhea, and difficulty breathing. By targeting both the 2a and 2d genotypes, this new formulation provides a more comprehensive approach to herd health management.

October 13, 2026: Boehringer Ingelheim launched the vaccine in Canada.
Over the past decade: PCV2d became the predominant genotype in Canada.

Culture Shift

This product launch follows the broader shift where PCV2d became the predominant swine circovirus genotype in Canada over the past decade. The industry is moving toward combined-genotype vaccines to replace older single-strain solutions in response to these evolving epidemiological patterns.

For Canadian pork producers, this single-dose vaccine simplifies the vaccination routine compared to previous multi-step protocols. Adopting the new genotype coverage may reduce herd health risks and associated losses from porcine circovirus associated disease.

The takeaway

Producers should evaluate their current herd vaccination schedules to determine if transitioning to this dual-genotype protection is beneficial. Integrating updated vaccines can help mitigate the long-term impacts of shifting viral strains on animal welfare and production efficiency.